PODD Add to watchlist $159.12 2.94 (-1.81%) Last updated: Jul 15, 2026 02:26
52-Week Range
$159.12
$138.79 $159.12 $354.88

Fundamentals Overview

Insulet Corp. is near the low of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 36.9 P/B 8.55 P/S 3.8

Profitability

Net margin 10.4%

Risk (Beta)

1.11 — in line vol

Earnings & growth

EPS $4.31 Rev -2.8% Profit -10.3% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 55% confidence Risk: Moderate Volatility — Beta 1.11. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -29.1% · 3M vs Healthcare sector: -26.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$11.02B
P/E (TTM)
36.89
EPS (TTM)
$4.31
Dividend Yield
N/A
52-Week Range
$138.79 - $354.88
Volume vs Avg
N/A
Beta
1.11

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that...
Sector: Healthcare
Headquarters: US
Employees: 5,400
IPO Date: May 2007
Beta: 1.11 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 12, Neutral: 5, Outperform: 10, Overweight: 2, Underweight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-37.16; current price is $159.12. That’s a -123.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 36.89
PEG (TTM) N/A
P/B (TTM) 8.55
P/S (TTM) 3.8
P/FCF (TTM) 26.74
Liquidity & enterprise
Current Ratio (TTM) 2.49
Quick Ratio (TTM) 1.81
Cash Ratio (TTM) 0.7
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 10.44%
Gross margin (TTM) 71.01%
Operating margin (TTM) 17.48%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for PODD.

Analyst Sentiment at a Glance

B Sentiment Weakening
Buy 12Neutral 5Outperform 10Overweight 2Underweight 1
0 upgrades, 2 downgrades
Price Target Consensus
Current $159.12
Median $213.00
Consensus $214.43
Low consensus $180.00
High consensus $249.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Truist Securities maintain Buy Buy 2026-07-13
RBC Capital maintain Outperform Outperform 2026-07-13
Stifel maintain Buy Buy 2026-07-10
Citigroup maintain Neutral Neutral 2026-07-08
Evercore ISI Group maintain Outperform Outperform 2026-07-06
Truist Securities maintain Buy Buy 2026-06-12
Citigroup maintain Neutral Neutral 2026-05-28
RBC Capital maintain Outperform Outperform 2026-05-27
BTIG maintain Buy Buy 2026-05-27
B of A Securities maintain Buy Buy 2026-05-18
Barclays maintain Underweight Underweight 2026-05-08
Oppenheimer maintain Outperform Outperform 2026-05-07
Truist Securities maintain Buy Buy 2026-05-07
Wells Fargo maintain Overweight Overweight 2026-05-07
Evercore ISI Group maintain Outperform Outperform 2026-05-07
RBC Capital maintain Outperform Outperform 2026-05-07
JP Morgan maintain Overweight Overweight 2026-05-07
Canaccord Genuity maintain Buy Buy 2026-05-07
Bernstein maintain Outperform Outperform 2026-05-07
Citigroup maintain Neutral Neutral 2026-05-06
BTIG maintain Buy Buy 2026-05-06
Rothschild & Co downgrade Buy Neutral 2026-04-24
Truist Securities maintain Buy Buy 2026-04-15
Goldman Sachs maintain Buy Buy 2026-04-09
Citigroup downgrade Buy Neutral 2026-04-07
Citigroup maintain Buy Buy 2026-03-11
Bernstein maintain Outperform Outperform 2026-02-19
Leerink Partners maintain Outperform Outperform 2026-02-19
Canaccord Genuity maintain Buy Buy 2026-02-19
Evercore ISI Group maintain Outperform Outperform 2026-02-19